Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.58 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.55 |
| ▸ | IL1RN | P18510 | 4/20 | 0.55 |
| ▸ | ECE1 | P42892 | 5/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 6/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30590781 | 0.96 | ERAP2 (0.56) | ERAP2ERAP1IL1RNECE1ANPEP | |
| SCHEMBL30590798 | 0.96 | ERAP2 (0.56) | ERAP2ERAP1IL1RNECE1ANPEP | |
| SCHEMBL29427859 | 0.93 | ERAP2 (0.63) | ERAP2ERAP1IL1RNECE1ANPEP | |
| SCHEMBL31615095 | 0.92 | GHSR (0.58) | GHSR | |
| SCHEMBL30590790 | 0.91 | ECE1 (0.53) | ERAP2ERAP1IL1RNECE1GHSR | |
| SCHEMBL31473234 | 0.91 | NPBWR1 (0.53) | ERAP2GHSR | |
| SCHEMBL31473233 | 0.91 | NPBWR1 (0.53) | ERAP2GHSR | |
| SCHEMBL29663506 | 0.91 | GHSR (0.52) | ERAP2ERAP1IL1RNECE1ANPEP | |
| SCHEMBL29516260 | 0.90 | ERAP2 (0.61) | ERAP2ERAP1IL1RNECE1ANPEP | |
| SCHEMBL30500405 | 0.90 | ECE1 (0.59) | ERAP2ERAP1IL1RNECE1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590325-B2 | Directed evolution for obtaining improved variants of TEV protease for biotechnological applications | CZ BIOHUB SF, LLC (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260074011-A1 | END-TO-END MACHINE LEARNING-DRIVEN DESIGN OF PROTEINS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2024044362-A1 | END-TO-END MACHINE LEARNING-DRIVEN DESIGN OF PROTEINS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230067225-A1 | IMPROVED VARIANTS OF TEV PROTEASE FOR BIOTECHNOLOGICAL APPLICATIONS | CHAN ZUCKERBERG BIOHUB, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590325-B2 | Directed evolution for obtaining improved variants of TEV protease for biotechnological applications | CRY2, CRY1, CRYZ | ERAP2 190/4885ERAP1 105/4885IL1RN 4369/4885 |
| US-20260074011-A1 | END-TO-END MACHINE LEARNING-DRIVEN DESIGN OF PROTEINS | SET, MAX, FCGR3B | ERAP2 1475/4885ERAP1 353/4885IL1RN 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.